NICE has endorsed idebenone (Raxone) on the NHS to treat Leber’s hereditary optic neuropathy in individuals aged 12 and over, offering hope to around 250 people.
Dr Nazneen Rahman, Founder and CEO of YewMaker and Sustainable Medicines Partnership (SMP) Director describes why digital medicine information is essential for sustainable medicines.
David Bloomfield, Consultant in Clinical Oncology Sussex Cancer Centre, argues that precision radiotherapy is our most effective cancer treatment and should be available to everyone with cancer, but workforce planning is failing our patients.
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses different tuberculosis drug development regimens.
As the first alternative for non-invasive treatment of kidney stones, ultrasound bursts can actually break up kidney stones – making it easier for them to pass on their own.
A new study on HIV medication treatment discovered persistent disparities between sex and age, potentially subjecting women to worse HIV treatment outcomes on the drug dolutegravir.
A new study, published in AIDS and Behavior, finds that healthcare providers still have some social bias about who should be given PrEP - the HIV prevention drug.
Doris-Ann Williams MBE, CEO, BIVDA, calls for increased community testing as a way to clear the NHS backlog and deal with the increasing number of people who are living with undiagnosed diseases in the UK.
